Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and tolerability of IGSC 20% in Japanese PID patients (extension of TAK-664-3001)
jRCT2041210006Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2021
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of polyvalent human immunoglobulin in Immunogenetic disorder, sponsored by Takeda. Primary endpoints: Number of participants with treatment-emergent adverse events (TEAEs), serious TEAEs, and non-serious TEAEs, Number of participants with drug-related and non-related TEAEs and 2 more. Started Apr 2021; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
Immunogenetic disorder
Beyond the preview
Go deeper on jRCT2041210006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210006.